Implant Sciences Corporation and OSI Systems Resolve Legal Dispute
Implant Sciences zu myNews hinzufügen Was ist das?
Implant Sciences Corporation (AMEX: IMX) a leading developer of
advanced explosives detection products and technology, today announced
the resolution of the legal dispute between the Company and OSI Systems,
Inc. regarding the Development, Distribution and Manufacturing Agreement
entered into in 2005. Under the terms of the resolution, the parties
rescinded the previous agreement and entered into a new non-exclusive
distribution agreement for Rapiscan Systems, a wholly owned subsidiary
of OSI Systems, to sell Implant Sciences security products worldwide.
Phillip C. Thomas, Implant Sciences Chairman and CEO, commented, "The
Company has put an end to the distraction and drain on financial and
human resources being expended on this dispute. As such, our team will
now be more focused on increasing sales and accelerating the development
of new products as we continue our push toward profitability. This
resolution also places us in a position where we can work cooperatively
with a recognized leader in the imaging portion of the security market
and provides the opportunity to leverage Rapiscan’s
distribution channels to enhance worldwide sales of our handheld and
benchtop trace explosives detection products. This outcome is additive
for both companies and establishes the basis for a positive business
relationship for both firms. We look forward to collaborating with OSI
and Rapiscan on current and new opportunities in the sale of our
security products.” About Implant Sciences
Implant Sciences develops, manufactures and sells products through its
primary business units: (i) explosives trace detection (ETD) systems for
homeland security, defense, and other security related applications and
(ii) state of the art services for the medical and semiconductor
industries. The Company has developed proprietary technology used in its
commercial portable and bench-top ETD systems, which ship to a growing
number of locations domestically and around the world.
The Company’s ETD products and developments
address many important security needs in aviation, cargo,
transportation, and other related elements of the government and
commercial infrastructure. In addition to its security market focus, the
Company provides high technology coatings for a variety of medical
products at its main facility in Wakefield, Massachusetts and provides
ion implantation services to the semiconductor industry from its
location in Sunnyvale, California. For further details on the Company
and its products, please visit the Company’s
new website at www.implantsciences.com.
Implant Sciences believes this press release contains forward-looking
statements as that term is defined in the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements are subject to risks
and uncertainties. Such statements are based on management's current
expectations and are subject to facts that could cause results to differ
materially from the forward-looking statements.
For further information, you are encouraged to review Implant Sciences’
filings with the Securities and Exchange Commission, including its
Annual Report on Form 10K for the period ended June 30, 2007 and
Quarterly Report for the period ended September 30, 2007. The Company
assumes no obligation to update the information contained in this press
release.